School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Lineage Cell Therapeutics, Inc. LCTX

Healthcare · Biotechnology

$0.95last close 2026-10-12 · market cap $241.30M · delayed data

Trailing returns

1M-5.94%
3M-25.78%
6M-35.81%
1Y-42.77%
5Y-61.22%

Basis: Adjusted daily closes.

What it does

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.

Open LCTX in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies